Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D9723C00001
AstraZeneca AB
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
1 trial -
D9727C00001
AstraZeneca AB
Prostate Cancer
1 trial -
D9802C00001
AstraZeneca AB
Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
1 trial -
DANUBE/D419BC00001
AstraZeneca AB
Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.
1 trial -
DESTINYEndometrial01
AstraZeneca AB
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
1 trial -
DUO-O/D081RC00001
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
Dapagliflozin
AstraZeneca
Type 2 Diabetes
3 trials -
Dapagliflozin
AstraZeneca
Type 2 Diabetes Mellitus
2 trials -
Dapagliflozin
AstraZeneca
Heart Failure With Preserved Ejection Fraction (HFpEF)
1 trial -
Dapagliflozin
AstraZeneca
Heart Failure With Preserved Ejection Fraction
1 trial -
Dapagliflozin
AstraZeneca
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
1 trial -
Dapagliflozin 10 mg
AstraZeneca
Diabetes Mellitus, Non-Insulin-Dependent
1 trial -
Dapagliflozin 10 mg
AstraZeneca
Type 2 Diabetes Mellitus
1 trial -
Dato-DXd
AstraZeneca
Breast Cancer
2 trials -
Datopotamab deruxtecan for Stage I-III Triple-negative Bre…
AstraZeneca AB
Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.
1 trial -
Datopotamab deruxtecan, DOCETAXEL
AstraZeneca AB
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.
1 trial -
Docetaxel
AstraZeneca
Prostate Cancer
1 trial -
Durvalumab
AstraZeneca
Advanced Hepatocellular Carcinoma
1 trial -
Durvalumab
AstraZeneca
Non Small Cell Lung Cancer NSCLC
1 trial -
Durvalumab
AstraZeneca
Cancer
1 trial -
Durvalumab
AstraZeneca
Carcinoma, Non-Small-Cell Lung
1 trial -
Durvalumab
AstraZeneca
Hepatocellular Carcinoma
2 trials -
Durvalumab
AstraZeneca
Locally Advanced Cervical Cancer
1 trial -
Durvalumab
AstraZeneca
Muscle Invasive Bladder Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.